Non enzymatic glycated proteins in the blood and cardiovascular disease

Current Pharmaceutical Design

Volumn 13, Issue 36, 2007, Pages 3688-3695

  Misciagna, G ^a   De Michele, G ^a   Trevisan, M ^b  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cardiovascular disease; Fructosamine; Glycated apolipoprotein B; Glycated hemoglobin

Indexed keywords

ACETALDEHYDE; ACETYL COENZYME A; ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CYANIC ACID; FRUCTOSAMINE; FRUCTOSE; GLUCOSE 6 PHOSPHATE; GLYCERALDEHYDE 3 PHOSPHATE; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED PROTEIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; PENICILLIN G; UREA; VITAMIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLORIMETRY; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCATION; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN TARGETING; REVIEW; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; FRUCTOSAMINE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPOPROTEINS, LDL; RISK FACTORS;

EID: 37449025486     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207783018545     Document Type: Review

References (130)

1. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 25: 436-72.
2. Liu K, Stamler J, Stamler R, Cooper R, Shekelle RB, Schoenberger JA, et al. Methodological problems in characterizing an individual's plasma glucose level. J Chron Dis 1982; 35: 475-85.
3. Duncan BB, Heiss G. Non enzymatic glycosylation of proteins, a new tool for assessment of cumulative hyperglycemia in epidemiological studies, past and future Am J Epidemiol 1984; 120: 169-89.
4. 1c level. Diabetes Care 2000; 23: 1830-4.
5. 1c, distribution in a healthy population. Diabetologia 1989; 32: 864-9.
6. Gulliford MC, Ukoumunne OC. Determinants of glycated haemoglobin in the general population: association with diet, alcohol and cigarette smoking. Eur J Clin Nutr 2001; 55: 615-23.
7. Boeing H, Weisgerber UM, Jeckel A, Rose HJ, Kroke A. Association between glycated hemoglobin and diet and other lifestyle factors in a non diabetic population: cross-sectional evaluation of data from the Potsdam cohort of the EPIC Study. Am J Clin Nutr 2000; 71: 1115-22.
8. 1c, levels. Diabetes Care 2001; 24: 1911-6.
9. Sargeant LA, Wareham NJ, Bingham S, Day NE, Luben RN, Oakes S, et al. Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (Epic-Norfolk) study. Diabetes Care 2000; 23: 726-32.
10. 1c, with prevalent cardiovascular disease in the original cohort of the Framingham heart study. Diabetes 1992; 41: 202-8.
11. Browner WS, Pressman AR, Lui LY, Cummings SR. Association between serum fructosamine and mortality in elderly women. The Study of Osteoporotic Fractures. Am J Epidemiol 1999; 149: 471-5.
12. Maillard LC. Action des acides amines sur les sucres: Formation des melanoiddines par voie méthodique. C R Acad Sci 1912; 154: 66.
13. Banting FG, Best CH, Collip JB. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922; 12: 141-6.
14. Yaylayan VA, Huyghues-Despointes A. Chemistry of Amadori rearrangement products: analysis, synthesis, kinetics, reactions, and spettroscopic properties. Crit Rev Food Sci Nutr 1994; 31: 321-69.
15. Tsilibary EC, Charonis AS, Reger LA, Wohlhueter RM, Furcht Lt. The effect of non-enzymatic glycosylation on the binding of the main noncollagenous NC-1 domain to type IV collagen. J Biol Chem 1988; 263: 302-8.
16. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. J Biol Chem 1991; 266: 11649-53.
17. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. J Biol Chem 1991; 226: 11654-60.
18. ε-(carboxymethyl)lysine in alkaline condition. FEBS Lett 1998; 425: 355-60.
19. ε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-68.
20. Brownlee M. Nonenzymatic glycosylation of macromolecules. Diabetes 1992; 41: 57-60.
21. Bunn HF, Higgins PL. Reaction of monosaccharides with proteins: possible evolutionary significance. Science 1981; 213: 222-4.
22. Deyl Z, Mikšik I. Post-translational non-enzymatic modification of proteins I. Chromatography of marker adducts with special emphasis to glycation reactions. J Chromatogr B 1997; 699: 287-9.
23. Kennedy L, Mehl TD, Elder E, Varghese M, Merimee TJ. Nonenzymatic glycosylation of serum and plasma protein. Diabetes 1982; 31: 53-6.
24. Allgrove J, Cockrill B. Fructosamine or glycated haemoglobin as a measure of diabetic control? Arch Dis Child 1998; 63: 418-22.
25. Bucala R. Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. Exp Physiol 1997; 82: 327-33.
26. Means GE, Chang MK. Nonenzymatic glycosylation of proteins, structure and function changes. Diabetes 1982; 31: 1-4.
27. Vlassara H. Recent progress in advanced glycation end products and diabetic complication. Diabetes 1997; 46: S19-24.
28. Baisier WM, Labuza TP. Maillard browning kinetics in a liquid model system. J Agric Food Chem 1992; 40: 707-13.
29. Higgins PJ, Bunn HF. Kinetic analysis of the non enzymatic glycosylation of hemoglobin. J Biol Chem 1981; 256: 5204-8.
30. Schleicher E, Wieland OH. Kinetics analysis of glycation as a tool for assessing the half-life of proteins. Biochern Biophys Acta 1986; 884: 199-205.
31. lc. J Clin Inv 1976; 57: 1652-9.
32. lc formation in human erythrocytes in vitro. J Clin Invest 1982; 69: 1164-8.
33. lc by automated 'high-performance' liquid chromatography. Clin Chem 1979; 25: 1970-1.
34. Kelly SB, Olerud JE, Witzum JL, Curtiss LK, Gown AM, Odland GF. A method for localizing the early products of nonenzymatic glycosylation in fixed tissue. J Clin Derm 1989; 93: 327-31.
35. Lorenzi M, Cagliero E, Markey B, Day NE, Luben RN, Oakes S. Interaction of human endothelial cells with elevated glucose concentrations and native glycosylated low density lipoproteins. Diabetologia 1984; 26: 219-22.
36. Mullokandov E, Carrol Z, Yoakum G. Advanced glycosylation products damange DNA by generating apuric apyrimidinic sites. Diabetes 1991; 40: 1075A.
37. Bucala R, Mokel P, Cerami A. Modification of DNA by reducing sugar: a possible mechanism for nucleic acid aging and age related dysfunction in gene expression. Proc Natl Acad Sci USA 1984; 81: 105-9.
38. Lee AT, Cerami A. Elevated glucose 6-phosphate levels are associated with plasmid mutations in vivo. Proc Natl Acad Sci USA 1987; 84: 8311-4.
39. Lorenzi M, Montisano DF, Toledo S, Wong HC. High glucose and DNA damage in endothelial cells. J Clin Invest 1986; 77: 322-5.
40. Lee AT, Cerami A. The formation of reactive intermediate(s) of glucose 6-phosphate and lysine capable of rapidly reacting with DNA. Mutat Res 1987; 179: 151-8.
41. Mikšík I, Hodný Z, Deyl Z. Chromatographic separation of glycated nucleotides. J Chromatogr 1993; 612: 56-61.
42. Szwergold BS, Howell S, Beisswenger PJ. Human Fructosamine-3 Kinase. Purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 2001; 50: 2139-47.
43. Ming Li Y, Steffes M, Donnelly T, Liu C, Futh H, Basgen J, et al. Prevention of cardiovascular and pathology of aging by the advanced glycation inhibitor amimoguanidine. Proc Natl Acad Sci USA 1996; 93: 3902-7.
44. Dunn PJ, Cole RA, Soeldner JS. Further development and automation of high pressure liquid chromatography method for the determination of glycosylated hemoglobins. Metabolism 1979; 28: 777-9.
45. Subramanian CV, Radhakrishnamurthy B, Berenson GS. Photometric determination of glycosylated hemoglobin in diabetes mellitus. Clin Chem 1980; 26: 1683-7.
46. lc. FEBS left 1976; 71: 356-60.
47. Da Costa J, Hess R, England J, Peth S. Measurement of glycosylated hemoglobin: comparison of colorimetric and ion-exchange chromatography methods. Diabetes 1980; 29: 273A.
48. Ney KA, Colley KJ, Pizzo SV. The standardization of the thiobarbituric acid assay for non enzymatic glucosylation of human serum albumin. Anal Biochem 1981; 118: 294-300.
49. lc. N Z Med J 1997; 110: 460-2.
50. Allen DW, Schroeder WA, Balog J. Observations on the chromatographic heterogeneity of normal adult and fetal hemoglobin. J Am Chem Soc 1958; 80: 1628-34.
51. Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. New Engl J Med 1971; 284: 353-7.
52. 1c. Arch Pathol Lab Med 1999; 123: 763-7.
53. Diamant Analyzer System, instruction manual. Richmond CA, Bio-Rad Laboratories 1992.
54. lc: Nature of the N-terminal beta chain blocking group. Biochem Biophys Res Commun 1968; 32: 86-93.
55. lc. Biochemistry 1966; 5: 2489-503.
56. Davison MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin. (Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria). JAMA 1999; 13: 1203-10.
57. Dix D, Cohen P, Kingsley S, Senkbeil J, Sexton K. Glycohemoglobin and glucose tolerance test compared as indicators of borderline diabetes. Clin Chem 1979; 25: 877-9.
58. Smart LM, Howie AF, Young RJ, Walker SW, Clarke BF, Smith AF. Comparison of fructosamine with glycosylated hemoglobin and plasma proteins as measures of glycemic control. Diabetes Care 1988; 11: 433-6.
59. Dunn PJ, Cole RA, Soeldner JS. Temporal relationship of glycosylated haemoglobin concentrations to glucose control in diabetics. Diabetologia 1979; 17: 213-20.
60. Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum control of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1982; 127: 87-95.
61. Schleicher ED, Vogt BW. Standardization of serum fructosamine assay. Clin Chem 1990; 36: 136-9.
62. Svendsen PA, Christiansen JS, Welinder B, Nerup J. Fast glycosylation of hemoglobin. Lancet 1979; i: 603.
63. Timothy J L. Lipoprotein glycation and its metabolic consequence. Diabetes 1992; 41: 67-73.
64. Wolffenbutte BHR, Giordano D, Founds HW, Bucala R. Longterm assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996; 347: 513-5.
65. lc. J Biol Chem 1977; 252: 2992-7.
66. Bunn HF, Shapiro R, McManus M. Structural heterogeneity of human hemoglobin A due to non enzymatic glycosylation. J Biol Chem 1979; 254: 3892-8.
67. Kunkel HG, Wallenuis G. New hemoglobins in normal adult blood. Science 1955; 122: 88.
68. Ryle AJ, Davie S, Gould BJ, Yudkin JS. A study of the effect of diet on glycosylated haemoglobin and albumin levels and glucose tolerance in normal subjects. Diabet Med 1990; 7: 865-70.
69. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivates on assay for glycohemoglobin. Clin Chem 2001; 47: 153-63.
70. lc determinations in patients with hemoglobinopaties. Diabetes Care 1999; 22: 638-9.
71. lc in type 1 diabetes mellitus. Pediatr Int 1999; 41: 357-62.
72. Panzer S, Kronik G, Lecher K, Bettelheim P, Neumann E, Dudczak R. Glycosylated hemoglobin (GHb): an index of cell survival. Blood 1982; 59: 1348-50.
73. Mosca A, Carenini A, Zoppi F, Carpinelli A, Banfi G, Cerlitti F, et al. Plasma protein glycation as measured by fructosamine assay. Clin Chem 1987; 33: 1141-6.
74. Desjarlais F, Comtois R, Beauregard H, Nguyen M, Letellier G. Technical and clinical evaluation of fructosamine determination in serum. Clin Biochem 1989; 22: 329-35.
75. Schleicher ED, Mayer R, Wagner EM, Gerbitz KD. Is serum fructosamine assay specific for determination of glycated serum protein? Clin Chem 1988; 34: 320-3.
76. Howey JEA, Browning MCK, Fraser CG. Assay of serum fructosamine that minimizes standardization and many problem: use to assess components of biological variation. Clin Chem 1987; 30: 269-72.
77. Kennedy AL, Mehl TD, Merimee TJ. Nonenzymatic glycosylated serum proteins: spurious elevation due to free glucose in serum. Diabetes 1980; 29: 413-5.
78. Coussons PJ, Jacoby J, McKay A, Kelly SM, Price NC, Hunt JV. Glucose modification of human serum albumin: a structural study. F Rad Biol Med 1997; 22: 1217-27.
79. Olufemi S, Talwar D, Robb DA. The relative extent of glycation of hemoglobin and albumin. Clin Chim Acta 1987; 163: 125-36.
80. Lyons TJ. Lipoproteins glycation and its metabolic consequences. Diabetes 1992; 41: 67-73.
81. Flückiger R, Woodtli T, Berger W. Evaluation of the fructosamine test for the measurement of glycated plasma protein. Diabetologia 1987; 30: 648-52.
82. Winocour PH, Bhatnagar D, Kalsi P, Hillier VF, Anderson DC. Relative clinical usefulness of glycosylated serum albumin and fructosamine during short-term changes in glycemic control in IDDM. Diabetes Care 1989; 12: 665-72.
83. lc glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995; 18: 440-7.
84. lc in evaluating the achievement of therapeutic goals in diabetes? Diabetes Metab 2001; 24: 598-603.
85. Day J, Ingebretsen CG, Ingebretsen WR, Baynes JW, Thorpe SR. Non-enzymatic glucosylation of serum proteins and hemoglobin: response to changes in blood glucose levels in diabetic rats. Diabetes 1980; 29: 524-7.
86. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor Miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Diabetes Care 1996; 19: 559-63.
87. Dieijen-Visser MP, Seynaeve C, Brombacher PJ. Influence of variations in albumin or total-protein concentration on serum fructosamine concentration. Clin Chem 1986; 32: 1610.
88. Constantini C, Simo JM, Joven J, Camps J. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: the influence of hypoalbuminemia and hypergammaglobulinemia. Ann Clin Biochem 1992; 29: 437-42.
89. Cirillo R, Balzano S, Cossu E, Bartalena L, Solinas P, Falcone M, et al. The effect of altered thyroid function on serum fructosamine concentrations. Clin Biochem 1988; 21: 179-81.
90. Comtoins R, Couturier M, Ammann H. Influence of protein and albumin levels on serum fructosamine concentration in a diabetic patient with multiple myeloma. Clin Biochem 1994; 27: 421-3.
91. Shea E, Cohen MP. Immunologic detection of glycated apolipoprotein B with site specific monoclonal antibodies. J Immunol Methods 1993; 162: 85-95.
92. De Michele G, Correale M, Guerra V, De Michele O, Misciagna G. Glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non diabetic subjects. Unpublished observations.
93. Stahl AJC, Rima A, Blickle JF, Brogard JM. Short-term variations of serum glycated apolipoprotein B. Diabetes Metab 1998; 24: 151-5.
94. Schleicher E, Deufel T, Wieland OH. Non-enzymatic glycosytation of human serum lipoproteins. Elevated €-lysine glycosylated low density lipoprotein in diabetic patients. FEBS Lett 1981; 129: 1-4.
95. Kim HJ, Kurup IV. Nonenzymatic glycosylation of human plasma low density lipoproteins: Evidence for in vitro and in vivo glycosylation. Metabolism 1982; 31: 348-53.
96. Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc Natl Acad Sci USA 1998; 95: 7643-7.
97. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinbeig D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1992; 31: 283-91.
98. Triau JE, Arbetter J, Schaefer EJ. Impaired hepatocyte binding, uptake and degradation of glucosylated low-density lipoproteins. Biochim Biophys Acta 1986; 877: 359-65.
99. Sasaki J, Okamura T, Cottam GL. Measurement of receptor-independent metabolism of low-density lipoprotein: An application of glycosylated low-density lipoprotein. Eur J Biochem 1983; 131: 535-8.
100. Krämer-Guth A, Quaschning T, Galle J, Baumstark W, Königer M, Nauck M. et al. Structural and compositional modifications of diabefic low-density lipoproteins influence their receptor-mediated uptake by bepatocytes. Eur J Clin Invest 1997; 24: 460-8.
101. Lyons TJ, Jenkins AJ. Glycation, Oxidation, and lipoxidation in the development of the complication of diabetes: a carbonyl stress hypothesis. Diabetes Rev 1997; 5: 365-91.
102. Brown MS, Goldstein JL. Familiar hypercholesterolemia: genetic, biochemical and pathophysiologic consideration. Adv Intern Med 1975; 20: 273-96.
103. Lops-Virella MF, Klein RK, Lyons TJ, Stevenson HC. Glycosylation of low-density lipoprotein enhances cholesterol ester synthesis in human monocyte-derived macrophages. Diabetes 1988; 37: 550-7.
104. Feingold K, Grunfeld C, Pang M. Doerrler W, Krauss R. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb 1992; 12: 1946-52.
105. Matsui H, Okumura K, Toki Y, Hayakawa T. Low-density lipoprotein particle size as an independent predictor of glycated low-density lipoprotein level. Diabetes Care 1999; 33: 1220-1.
106. Ganda OP, Day JL, Soelgner JS, Connon JJ, Gleason RR. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes 1978; 27: 715-25.
107. Sosenko M, Kubrusly DB, Goldberg RB, Fournier AM, Hsia L, Gadia MT, et al. High-density lipoprotein and glycosylated hemoglobin in nondiabetic individuals. Arch Intern Med 1986; 146: 1521-4.
108. McGill HC, Mcmahan A, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol 1995; 15: 431-40.
109. Temelkova-Kurktschjev T, Koehler C, Schaper F, Henkel E, Hahnefeld A, Fuecker K, et al. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia 1998; 41: 706-12.
110. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease. Than fasting or post challenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 1996; 19: 450-6.
111. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfotk). BMJ 2001; 322: 15-8.
112. Misciagna G, Logroscino G, De Michele G, Guerra V, Cisternino AM, Caruso MG, et al. Glycated apolipoprotein B and myocardial infarction. Nutr Metab Cardiov Dis 2007; 17: 6-12.
113. Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997; 3: 617-27.
114. Kiuchi K. Nejima J. Takano T. Ohta M. Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 2000; 85: 87-91.
115. Kanauchi M. Tsujimoto N. Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001; 24: 1620-3.
116. Tames FJ, Mackness MI, Arrol S, Laing I, Durrington PN. Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 1992; 93: 237-44.
117. Cohen MP, Lautenslager G, Shea E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 1993; 31: 707-13.
118. Akanji AO, Abdella N, Mojiminiyi OA. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002; 317: 171-6.
119. Millican SA, Schultz D, Bagga M, Coussons PJ, Muller K, Hunt JV. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Rad Res 1998; 28: 533-42.
120. Ferretti G, Rabini RA, Bacchetti T, Vignini A, Salvofini E, Ravaglia F, et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87: 2180-4.
121. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Comm 1990; 173: 932-9.
122. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoproteins is more sensitive to oxidation: implications for the diabetic patients. Atherosclerosis 1993; 102: 63-7.
123. Krauss RM. Lipids and lipoproteins in patients with type II diabetes. Diabetes Care 2004; 27: 1496-504.
124. Belle M, Krauss RM. Differences in carbohydrate content of low density lipoproteins associated with low density lipoprotein subclass pattern. J Lipid Res 1990; 31: 1577-88.
125. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, et al. Cigarette smoking and glycaemia: the EPIC Norfolk Study. Int J Epidemiol 2001; 30: 547-54.
126. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, et al. Fruit and vegetable intake and population glycosylated hemoglobin levels: the EPIC-Norfolk study. Eur J Clin Nutr 2001; 22: 342-8.
127. Misciagna G, De Michele G, Cisternino AM, Guerra V, Logroscino G, Freudenheim JL. Dietary carbohydrates and glycated proteins in the blood in non diabetic subjects. J Am Coll Nutr 2005; 24: 22-9.
128. Calkin AC, Jandeleit-Dahm KA, Sebekova E, Allen TJ, Mizrahi J, Cooper ME, et al. PPARs and diabetes-associated atherosclerosis. Curr Pharm Des 2007; 13(26): 2736-41.
129. Nilsson J, Nordin Fredrikson G, Schiopu A, Shah PK, Jansson B, Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Curr Pharm Des 2007; 13(10): 1021-30.
130. Shah PK. Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach. Curr Pharm Des 2007; 13(10): 1031-8.